Objective: The aim of this study was to determine the effect of statins and hormone therapy on submaximal exerciseYinduced coronary artery blood flow in postmenopausal women without a history of coronary artery disease. Hormone therapy or statin therapy in early postmenopausal women without coronary artery disease has been shown to enhance arterial endothelial function; we hypothesized that these agents would improve submaximal exerciseYinduced coronary artery blood flow.
F
or older postmenopausal women, particularly those with existing coronary artery disease (CAD), hormone therapy (HT) does not reduce the risk of future cardiac events 1<3 nor favorably enhances arterial endothelial function. 4 However, in middle-aged women without known CAD who began HT early after menopause, results from several studies have shown that HT may reduce the incidence of future cardiac events and improve endothelial function. 5<8 Perhaps, HT may exert benefits on arterial function depending on a woman's age or the presence of atherosclerosis.
Three hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to enhance arterial endothelial function in postmenopausal women. 9 Statins exert other beneficial effects on the cardiovascular system through reduction of inf lammation and serum low-density lipoprotein cholesterol (LDL-C). 9 Statin therapy may have an additional benefit in women receiving HT: in a post hoc analysis of the Heart and Estrogen/Progestin Replacement Study (HERS) trial, women receiving statins exhibited an attenuated risk of cardiovascular events, including myocardial infarction (MI), when compared with women receiving HT without statin therapy. 9 Because both HT and statins have been associated with lower rates of MI, and these therapies favorably influence arterial endothelial function in women without known CAD, we hypothesized that both HT and statins may also favorably influence coronary artery blood flow (CABF) and the response of CABF to low to moderate levels of stress exercise. Accordingly, this study was performed to assess the effects of HT and/or statin therapy on resting and submaximal exerciseYinduced CABF in postmenopausal women without documented CAD.
METHODS

Study population and design
This study was approved by the institutional review board at the Wake Forest University School of Medicine, and all participants provided informed consent. This randomized, double-blind, placebo-controlled trial (awarded through NIH M01-RR07122) began recruitment in March 1, 2000. The trial was designed to enroll women in a 2 Â 3 factorial design testing the independent and joint effects of 80 mg/day of atorvastatin (ATORV) and two HT treatments (Fig. 1) . The women were randomized to receive ATORV or placebo pills with equal probability. The effect of the HT treatments was assessed using a crossover design in which participants were assigned to receive three 8-week treatment periods of (1) placebo, (2) conjugated equine estrogens (CEE) 0.625 mg, or (3) CEE 0.625 mg + medroxyprogesterone acetate (MPA) 2.5 mg. The order of these three treatments was established using a randomized block (on time) design. Each woman was randomly assigned to one of the six possible orders for the receipt of the three hormone/placebo treatments with equal probability. Each treatment period was preceded by a 6-week period of no therapy (Fig. 1) . At the end of each treatment period, 10 mg of MPA was given on 10 successive days to induce menses and thus abort any induction of endometrial hyperplasia.
Women eligible for this study included those aged 50 to 65 years with a serum follicular-stimulating hormone level greater than 40 mIU/mL and no natural menses for at least 1 year, or a documented oophorectomy and a serum estrone level less than 25 pg/mL. Before study participation, women who previously used HT could enroll in the study if they abstained from HT 8 weeks before study enrollment. Eligible participants had no historical, physical examination, or electrocardiogram evidence of CAD.
Participants were recruited by obtaining mailing lists of addresses of all women between the age of 50 and 65 years within a 15Yzip code (approximately 20 mile) radius of downtown Winston-Salem, a city in western North Carolina with a population of 290,000.
Women were excluded from participation if they had a history of current or prior breast or endometrial carcinoma, arterial or venous thrombus formation, symptomatic gallstone disease, fasting triglyceride levels greater than 400 mg/dL, active liver disease with a serum glutamic oxalacetic transaminase (SGOT) level greater than 40 U/L, class III or IV New York Heart Association heart failure, Mobitz II or III atrioventricular block, severe systemic hypertension, ventricular tachycardia, unstable angina, CAD (including history of angina, coronary artery revascularization, MI, or Q wave on 12-lead electrocardiogram), obstructive hypertrophic cardiomyopathy, atrial fibrillation with rapid ventricular response, moderate or severe aortic stenosis, severe obstructive or reactive FIG. 1 . Display of the randomization scheme for participants in the study. As noted, the CEE + MPA treatment groups (gray boxes) were omitted in the middle of the study because of results from the Women's Health Initiative indicating an increase in adverse cardiovascular events after receipt of this therapy. SGOT, serum glutamic oxaloacetic transanimase. airway disease, or a contraindication to magnetic resonance imaging (MRI) scanning (such as claustrophobia, pacemakers, defibrillators, or other implanted electronic devices).
Before, women began the study and after each 8-week treatment period, serum lipids and rest/stress MRI measurements of CABF were assessed. The SGOT and total creatine kinase (CK) levels were measured 14 weeks after women entered the study. To confirm compliance with each treatment period, pill counts and serum testing of estrone and estradiol were performed. Participants were considered compliant if (1) pill counts demonstrated that the woman took 85% of the prescribed pills (placebo or treatment), (2) their estrone level after receiving HT was 25 pg/mL or greater, and (3) their estrone level after a period of treatment without HT was 25 pg/mL or less.
MRI of CABF
The CABF was measured noninvasively with phase-contrast MRI according to previously published techniques.
10,11 MRI studies were performed on a 1.5-T GE CV/I whole-body imaging system (General Electric Medical Systems, Waukesha, WI) with participants positioned supine. A phased array cardiac surface coil positioned centrally over the chest was used as a radiofrequency receiver. Electrocardiographic monitoring leads and a brachial blood pressure cuff were applied for monitoring heart rate and systemic blood pressure throughout the examination.
The left anterior descending (LAD) coronary artery was imaged according to previously published techniques. 12 Once the LAD was visualized, we acquired our flow measurement 2.5 cm distal to the origin of the LAD at its bifurcation from the left main coronary artery. Using previously published reproducibility techniques, 10 we located the same position in the LAD throughout all of the repeat measurements acquired in the study. Magnetic resonance scan parameters included an 8-mm-thick slice, a 256 Â 256 matrix, a 20-cm field of view, a through-plane velocity encoding of 150 cm/second, a 45-flip angle, a 13.8-ms repetition time, and a 6.7-ms echo time. Segmented k-space and view sharing were used to obtain seven frames per R-R interval. Coronary artery blood flow was obtained for each slice position by multiplying the cross-sectional area of the vessel by the average of the flow velocity of blood in that vessel. 11, 13 After three flow measurements at rest were obtained (these values were averaged to obtain baseline flow), the participant was withdrawn from the bore to perform submaximal exercise on a nonferromagnetic electronically braked bike (Lode, Groningen, The Netherlands). 10 To maintain the position of the participant's torso for repeat artery imaging, the bike was mounted on the end of the MRI table, and the participant pedaled in a supine position. Also, according to previously published techniques, the participants were marked at the apex of their suprasternal notch to ensure repositioning after exercise. 10 After exercising 10 W for 1 minute, 25 W for 3 minutes, and 35 to 55 W for 3 minutes, the participant was advanced back into the scanner, and images and flow measurements were once again taken in the original slice positions used to obtain the flow measurements at rest. A single stress flow measurement was accomplished within 40 seconds of exercise cessation. The reproducibility of this technique has been established previously in 11 women undergoing repeated measures separated by 8 weeks. Repeated stress-rest changes in CABF in the LAD were highly correlated (r = 0.86), and using this technique, 24 participants are needed per group to detect a 20% difference in stress-rest difference in flow at 80% power.
Statistical analysis
Baseline population characteristics for categorical variables are presented as percentages, and continuous variables are presented as mean T SD. Comparisons of baseline measures between those randomized to ATORV for categorical variables were tested using Fisher's exact test, and continuous variables were tested using two-sided unpaired Student's t tests. Preliminary analyses considered the skewness and equal variances between treatment groups of the outcome variables. All means, SD, and/or errors are presented with original units. Because of positively skewed distributions, tests for statistical significance and P values for the outcome variables triglyceride, estrone, estradiol, and resting and stress CABF were analyzed using a logarithmic transformation.
All analyses of outcome measures were performed using SAS PROC MIXED procedures for repeated-measures twoway analysis of covariance, with the baseline value of the outcome measure as the covariate and terms in the model for period effect, lipid-lowering (statin) drug effect, hormone effect, and possible lipid drug and hormone interaction. Hormone therapy was the repeat factor with an unstructured covariance matrix specified. The SGOT and total CK levels were not measured at baseline, so they were not included as a covariate for the outcome measures. The data measured at the end of each HT treatment are expressed as least square means T SE. Except for comparisons between specific combination therapies for the total cholesterol to the high-density lipoprotein cholesterol (HDL-C) ratio, all other P values referred to comparisons with placebo.
The primary analysis for this randomized clinical trial was based on the intention-to-treat randomized assignment. Seven participants did not take their assigned medication (ATORV or HT). For these participants, a compliance with therapy analysis was performed in which the follow-up period outcome measures in which medical noncompliance occurred were set to missing.
The sample size estimate for this study was determined from a pilot crossover study on the effects of CEE on vascular reactivity that observed a 26% relative increase in activity due to CEE. This proposed trial addressing the effect of CEE and CEE + MPA was originally designed to have 80% power to detect half the estimated relative effect (13%) between these two HT groups. Based on estimates of variation and correlations from the pilot study, we estimated that a sample of 124 evaluable participants was needed to achieve the stated goal. In two previous trials we conducted with a similar follow-up period, we had a 13% dropout rate. Allowing for a 15% dropout rate, we planned to randomize 146 women to ensure participation of at least 124 evaluable women.
Midway through enrollment, the trial was stopped because of results from the Women's Health Initiative (WHI) study indicating an increase in cardiac events, strokes, and pulmonary thromboembolism upon receipt of estrogen in combination with progestin.
3 After 20 months of review by the National Institutes of Health, the institutional review board of the home institution, and the data safety monitoring board affiliated with the trial, it was determined to restart the study with a twoperiod crossover (placebo vs daily oral CEE 0.625 mg) and the randomization of ATORV or placebo. The CEE + MPA treatment period was removed (gray boxes in Fig. 1) . As a result, the enrollment period of the study was reduced from 36 to 16 months, and 64 rather than 146 participants were enrolled into the study. This sample size would still provide 95% power to detect to the overall 26% relative effect estimated in the pilot study between the HT groups versus the placebo and provide 80% power to detect an effect that is 80% of the originally estimated effect of CEE alone.
RESULTS
Sixty-four postmenopausal women aged 51 to 65 years were enrolled and randomized to receive treatment. Of these, eight participants did not continue with the study because of scheduling conflicts (n = 3) or the development of hot flashes after discontinuing HT before study entry (n = 5). As a result, 56 individuals underwent serial assessments of serum lipids, and of these, 47 women received an MRI; 9 individuals did not wish to participate in the MRI scanning. Demographic data regarding the participants are provided in Table 1 .
Before suspension of study enrollment due to the WHI study results, 14 participants received the combination of CEE 0.625 mg and MPA 2.5 mg and underwent MRI measures of CABF. No serious adverse events occurred in the study population. Nine participants experienced adverse events. Seven occurred in those receiving ATORV (four women with CK elevation in the range of 174-231 U/L and three women with abdominal or musculoskeletal pain). Two adverse events occurred in participants receiving HT without ATORV (one with vaginal bleeding and one with an elevation of CK to 237 U/L). In those with adverse events, therapy was discontinued for 2 to 6 weeks until the CK and SGOT levels returned to baseline levels or vaginal bleeding stopped. The individual with vaginal bleeding was evaluated by a gynecologist.
Intention-to-treat analysis
Hemodynamic data pertaining to exercise are shown in Table 2 . Although some of the resting and submaximal exercise induced measures of CABF trended higher than did values obtained with placebo, only the submaximal exerciseY induced measurement of CABF in participants receiving ATORV and CEE was higher than that in patients receiving placebo (83 T 5 vs 66 T 6 mL/min, respectively; P G 0.04) in the intention-to-treat analysis (Table 3) . Serum lipids for the participants are shown in Table 4 . In addition, the combination of HT and ATORV reduced the serum low-density lipoprotein cholesterol (LDL-C) level (P G 0.001), increased the serum HDL-C level (P G 0.001), and modified the total cholesterolYto-HDL-C ratio (P G 0.001).
Compliance with therapy analysis
A secondary analysis was performed based on participants who were compliant with therapy. The rest-and stress-induced changes in CABF in the LAD were 43 and 61 mL/minute, respectively, in those receiving placebo, 53 and 75 mL/minute in those receiving CEE (P = 0.03), 55 and 78 mL/minute in those receiving ATORV (P = 0.02), and 50 and 83 mL/minute in those receiving ATORV + CEE (P = 0.13). In those compliant with therapy, the submaximal exerciseYinduced change in CABF increased in those receiving ATORV (P = 0.047) or HT + ATORV (P = 0.016) compared with placebo. When stratified by age (50-59 and 60-65 y), the effects of HT on resting stress blood flow were neither statistically nor clinically different between the two strata.
DISCUSSION
Three findings are associated with this study. First, in postmenopausal women aged 50 to 65 years without a history of CAD, the combination of high-dose oral ATORV and CEE improves submaximal exerciseYinduced CABF. Second, in postmenopausal women aged 50 to 65 years without documented CAD who comply with the administration of 80 mg of ATORV or 0.625 mg of CEE per day, resting CABF improves by 24% to 28% (P = 0.02-0.03). Also, after submaximal exercise, the stress-rest difference in CABF increases by 28% after receipt of ATORV (P = 0.047), 22% after receipt of CEE, or 35% after receipt of ATORV + CEE (P = 0.016). The combination of CEE and ATORV reduced the serum LDL-C level, increased the serum HDL-C level, and reduced serum triglycerides (P = 0.001 for all).
Statin therapy reduces cardiovascular events, 14<17 atherogenesis, and inflammation and enhances arterial endothelial function.
14<19 These effects are mediated by enhancing the production of nitric oxide and/or reducing the formation of oxygen-derived free radicals. 20<23 In the current study, we studied the effects of statin therapy on submaximal exerciseY induced CABF because this is the level of exercise that most individuals perform through activities of daily living (such as grocery shopping or walking to the bus stop). 10 With our sample size, we were able to capitalize on the precision of MRI for detecting changes in CABF after submaximal exercise. Using this noninvasive, relatively novel technique, we were able to measure LAD CABF at the same location in the artery repeatedly over 14-week intervals throughout the study without exposing women to ionizing radiation, contrast material, or vasoactive sedation procedures that could perturb resting or submaximal exerciseYinduced CABF. Importantly, our data indicate that 80 mg/day of ATORV increases CABF in the LAD at rest and after submaximal exercise (P G 0.05) relative to placebo in postmenopausal women aged 50 to 65 years without a history of CAD.
Although HT enhances peripheral arterial endothelial function, 24 data from the WHI indicate that HT involving progestins increases the incidence of MI, stroke, and pulmonary embolism. Importantly, however, in a subgroup analysis of the WHI in women younger than 60 years without documented CAD in whom it was less than 10 years since the onset of menopause, fewer major cardiac events and coronary revascularization procedures were observed in women taking HT versus placebo. 25 To this end, our study addressed the effects of HT on submaximal exerciseYinduced CABF in postmenopausal women younger than 65 years without documented CAD. In those women taking 85% of their prescribed medicine regimen of CEE 0.625 mg/day or CEE + ATORV 80 mg/day, CABF at rest and after submaximal exercise improved relative to that of women taking placebo. These data indicate that CEE, particularly when combined with relatively high doses of ATORV, improves submaximal exerciseYinduced CABF, a level of activity for which many of these women perform through activities of daily living. This may provide insight into the potential mechanisms of reduced coronary events demonstrated in other studies.
This study was not designed to assess the relationship between CABF and serum lipid levels. However, the data from our study provide new insight into the combined effect of high-dose ATORV and CEE on serum lipid profiles in older women. Although HT modifies serum HDL-C levels 26, 27 and lowers LDL-C levels, CEE does not lower LDL-particle number; therefore, it may not be associated with the same benefits as a statin that lowers LDL-C levels. 28, 29 In postmenopausal women without CAD, we found that 80 mg/day of ATORV significantly decreased the total cholesterol level, LDL-C level, triglyceride level, and the cholesterolYto-HDL-C ratio (P G 0.001) but did not significantly change the serum HDL-C level (P = 0.25). Daily oral CEE 0.625 mg significantly decreased the serum LDL-C level (P G 0.01) and total cholesterolYto-HDL-C ratio (P G 0.001) but increased serum HDL-C (P G 0.01) and triglyceride (P G 0.01) levels (Table 4 ). Many studies, including one large randomized controlled trial, 27 have documented that estrogen therapy in postmenopausal women decreases serum total cholesterol and LDL-C levels while increasing serum HDL-C and triglyceride levels. In those receiving high-dose ATORV and CEE in this study, total serum cholesterol, LDL-C, and triglyceride levels, as well as the total cholesterolYto-HDL-C ratio, were reduced (P G 0.001). In addition, the serum HDL-C level was increased (P G 0.001). This occurred with a decrease in serum triglyceride levels.
Our study has some limitations. First, we were unable to achieve the targeted enrollment goals because of suspension of participant recruitment in the middle of the study as a result of the findings from the WHI indicating adverse cardiac events associated with estrogen/progestin HT. Because a potential benefit may exist for early postmenopausal women without CAD using estrogen alone, it was felt that the study enrollment could be resumed in a safe manner; no participants experienced serious adverse events related to the administration of HT in this study. Second, because we did not reach our target enrollment, several of the intention-totreat analyses were underpowered. A larger number of participants enrolled and studied could provide additional results and conclusions. Several of our results apply to those women who reliably took more than 85% of the prescribed therapies studied in this trial rather than the complete randomized sample. As a result, there may be a greater chance for residual confounding that could lead to a biased assessment of the effects of our single-therapy-drug (HT or ATORV) interventions. Third, most of the women in this study were white; we are uncertain of results in women of another race. Fourth, we did not test multiple doses of therapy (HT or ATORV), treat for periods longer than 8 weeks, obtain data on duration of prior receipt of HT, or have the ability to confirm an absence of CAD with invasive testing. For this reason, we have no data regarding these circumstances, and, thus, other studies would be needed to address these important questions. Finally, we studied CABF in the LAD coronary artery. We selected the LAD coronary artery because it supplies 40% of the blood flow to the left ventricular myocardium and disease processes affecting the LAD coronary artery are associated with adverse outcomes. We are uncertain of the influence of these therapies on submaximal exerciseYinduced blood flow in the right or left circumflex coronary arteries.
CONCLUSIONS
In conclusion, these data suggest that in relatively early postmenopausal women (aged 50-65 y) without documented CAD, ATORV or CEE therapy enhances submaximal exerciseYinduced CABF in the LAD coronary artery.
